Piramal Pharma Limited — Others, 14-05-2025: Resignation

Piramal Pharma Limited has announced a board meeting approving the audited financial results for the quarter and financial year ended March 31, 2025, reporting standalone total income of Rs. 5,493 Cr and net profit of Rs. 691 Cr for the year. The Board has proposed a final dividend of Rs. 0.14 per equity share, subject to shareholder approval. Leadership changes include the resignation of Mr. Neeraj Bharadwaj as Non-Executive Non-Independent Director and the appointment of Mr. Amit Jain from Carlyle as Additional Director. Mr. Jairaj Purandare was re-appointed as an Independent Director for a second term. The auditors issued clean opinions on both standalone and consolidated results.